- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02229500
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling
Regulating Appetite by Targeting Nutrient Delivery in the Gut
Obesity, with its associated co-morbidities, is a major public health challenge. It is estimated that by 2050, 60% of men and 50% of women will be clinically obese. Obesity is associated with increased risk of developing diabetes, cardiovascular disease, and certain cancers. The increasing epidemic of obesity has necessitated the study of the complex mechanisms underlying energy homeostasis. Food intake, energy balance and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY), have been shown to play an important role in regulating short-term food intake. Peripheral administration of PYY or GLP-1 enhances satiety and reduces food intake in animals and man. PYY, GLP-1 along with a host of other hormones are produced by the gut in response to nutrient availability in different regions of the gut and provide an exquisite mechanism of nutrient sensing in response to dietary intake. These hormones therefore represent potential targets in the development of novel anti-obesity treatments. A novel and attractive strategy to induce appetite regulation is the enrichment of foods with components that stimulate the release of GLP-1 and PYY. The short chain fatty acids (SCFA) produced by microbial fermentation of dietary fibre in the colon have been shown to stimulate the release of PYY and GLP-1 from rodent enteroendocrine L cells, via stimulation of the G-protein coupled free fatty acid receptors (FFAR) on colonic L cells. Of the SCFAs produced by colonic fermentation of dietary fibre, propionate has the highest affinity for FFAR 2. Furthermore, propionate is an end product of bacterial metabolism, and thus, unlike acetate, does not undergo conversion to other SCFAs. Increasing colonic propionate is therefore an attractive target for appetite modulation.
We have developed a novel delivery system for delivering propionate to the right site in the colon and we now wish to optimise the delivery of propionate to the colon in man using stable isotope labelling methods.
Study Overview
Status
Intervention / Treatment
Detailed Description
The role of SCFA in appetite regulation: SCFA have been shown to stimulate PYY and GLP-1 production in animal models and dietary fibre, of which SCFA are the major end products, induce appetite regulation in humans. However the evidence underpinning which dietary fibres induce appetite regulation in humans is very weak because of the difficulty in controlling studies with very high fibre intake. In a recent project funded under the BBSRC DRINC initiative (BB/H004815/1), we have the first direct evidence that SCFA can directly regulate appetite in humans. Prior to this study, in order to achieve production of SCFA to a level, which is high enough to induce appetite-regulating effects, very large amounts of dietary fibre (>25 g/d and up to 40 g/d) are required, and compliance with high fibre diets is poor due to gastrointestinal side effects. Furthermore, supplementing diets with mixed high fibre does not predictably or reliably increase colonic SCFA production or circulating levels of SCFA in all human populations because of the variability in gut microbial activity. Finally, orally administered SCFAs are not palatable and are rapidly absorbed in the small intestine where L cells are sparse. In our studies to date we have focussed on the SCFA propionate because it has the highest affinity for the receptors and is an end product of metabolism in the microbiota and therefore seems the obvious target to manipulate to investigate the effects of SCFA on appetite regulation. To overcome the unpalatably high levels of fermentable dietary fibre needed to significantly increase colonic propionate levels, and the unpredictability in the production of the resulting SCFAs, we have developed and tested a novel delivery system targeting the release of gram quantities of propionate in the proximal colon. We estimate that our delivery system may lead to a 2-8 fold increase in colonic propionate, a level very difficult to achieve through feeding a mixed fermentable fibre diet. This level of propionate production might have been observed in ancestral diets and in parts of rural Africa where dietary fibre intake is very high. We have also demonstrated that delivery system increases plasma propionate levels, reduces food intake in acute studies of appetite, and in a longer term study (24 weeks), positive effects on food intake, body composition, glucose homeostasis, circulating lipids, cholesterol and liver function, liver and visceral fat and weight management were observed. However, in these studies we pragmatically chose an preparation that could be produced at scale. The amount of propionate released can be varied which in itself may affect the rate and amount of propionate released. For an ingredient, with the potential to be incorporated into a wide variety of foodstuffs, we now wish to investigate the optimum delivery system preparation that delivers the maximal propionate dose in the least amount of material.
We plan to use non-invasive, stable isotope labelling methodologies to determine propionate bioavailability from a range of delivery system preparations, in order to determine the optimum preparation for delivering maximal propionate to the proximal colon.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Lanarkshire
-
Glasgow, Lanarkshire, United Kingdom, G4 0SF
- Glasgow Clinical Research Facility
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- overweight males (BMI 25-35 kg/m2) aged between 21 - 65
Exclusion Criteria:
- Weight change of > 3kg in the preceding 2 months
- Current smokers
- Substance abuse
- Excess alcohol intake
- Pregnancy
- Diabetes
- Cardiovascular disease
- Cancer
- Gastrointestinal disease
- Kidney disease
- Liver disease
- Pancreatitis
- Use of any medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
Inulin control, 10g/d for 7 days.
Isotope and appetite measurements on day 7
|
Other Names:
|
Experimental: Delivery system 1
Delivery system, 28.5% w/w propionate, 10g/d for 7 days.
Isotope and appetite measurements on day 7.
|
This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
|
Experimental: Delivery system 2
Delivery system, 54% w/w propionate, 10g/d for 7 days.
Isotope and appetite measurements on day 7.
|
This delivers approximately 5g of propionate to the colon per 10g dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to maximal 13C appearance in breath
Time Frame: over 24 hrs
|
The time to peak maximal excretion in breath 13C (measured in breath 13CO2) will be the primary outcome criterion
|
over 24 hrs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under curve of breath 13C excretion
Time Frame: over 24hrs
|
The area under the curve of breath 13C excretion (measured in 13CO2) will be determined to assess amount of propionate released.
|
over 24hrs
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of preparations on appetite
Time Frame: 0ver 8 hrs
|
The effect of different delivery system preparations on appetite will be determined by visual analog scale measurements and ad libitum food intake
|
0ver 8 hrs
|
Collaborators and Investigators
Investigators
- Principal Investigator: Douglas Morrison, PhD, University of Glasgow
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- BB/L004259/1_SUERC_1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Optimum Propionate Delivery to the Large Intestine
-
Dalhousie UniversityCompletedTo Determine the Change in Demonstrated Anesthesia Non-technical Skills After Delivery of the VAST CourseRwanda
-
Ali YavuzcanAli Yavuzcan; Duygu Yıldız Birden; Alper BaşbuğCompletedThe Aim of Our Study Was to Evaluate the Outcomes in Women Who Implemented the Enhanced Recovery After Surgery Protocol at Delivery by Cesarean DeliveryTurkey
-
University of ZurichUnknownLiver Diseases | Liver Neoplasms | Hepatectomy | Surgery | Secondary Malignant Neoplasm of Liver | Colon Cancer Liver Metastases | Malignant Neoplasm of Large Intestine Metastatic to LiverSwitzerland
-
Kırıkkale UniversityEnrolling by invitationSuspected Damage to Fetus From Other Disease in the Mother, Affecting Management of Mother, With Delivery | Patient Death or Serious Disability Associated With A Haemolytic Reaction Due to the Administration of ABO-Incompatible Blood or Blood ProductsTurkey
-
University College, LondonUniversity of Oxford; University of Plymouth; University of Birmingham; University... and other collaboratorsCompletedFetal Intrauterine Distress First Noted During Labor and or Delivery in Liveborn Infant | Team Based on Their Existing Guidelines and the Woman Consents to Have EFM and EFM is | PossibleUnited Kingdom, Ireland
-
Stony Brook UniversityRecruitingThe Primary Outcome is Preterm Delivery Before 28 Weeks Gestational Age Compared to Women With One vs Two Cerclages PlacedUnited States
-
Hospital Universitario Virgen de la ArrixacaNot yet recruitingLiver Diseases | Liver Transplantation | Liver Neoplasms | Gastrointestinal Stromal Tumors | Metastasis | Liver Metastases | Liver Transplant; Complications | Liver Cancer | Liver Transplant Disorder | Liver Carcinoma | GIST, Malignant | GIST | Metastases | Metastatic Liver Cancer | Gastrointestinal Stromal Tumor of... and other conditionsSpain
-
Affiliated Hospital to Academy of Military Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking...RecruitingAge Range ≥16 Years, Gender Unlimited | Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma | Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed | At Least One Positive Lesion According to the 2014... and other conditionsChina
-
Shanghai Public Health Clinical CenterUnknownTo Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma
-
University of PennsylvaniaCompletedWomen Admitted to Labor and Delivery for the Management of Preterm Labor and/or Preterm Premature Rupture of Membranes (PPROM)United States
Clinical Trials on Inulin
-
Scottish Universities Environmental Research CentreUniversity of Glasgow; NHS Greater Clyde and GlasgowCompletedObesity | OverweightUnited Kingdom
-
Eskisehir Osmangazi UniversityUnknownFunctional Constipation
-
Maastricht University Medical CenterCompleted
-
Imperial College LondonUniversity of GlasgowCompletedAppetite Regulation | Healthy Obesity, MetabolicallyUnited Kingdom
-
University of Illinois at Urbana-ChampaignRenal Research InstituteCompletedBone Diseases, Endocrine | Nutritional and Metabolic DiseasesUnited States
-
Augusta UniversityAmerican Gastroenterological Association FoundationCompletedInvestigation of Dietary Absorptive Capacity of Fructans in Healthy Subjects - A Dose Response StudyHealthy VolunteersUnited States
-
University of ReadingUnknownOverweight and ObesityUnited Kingdom
-
CindetecNucitec SA de CVCompleted
-
Second Xiangya Hospital of Central South UniversityNot yet recruitingType 1 Diabetes Mellitus | Autoimmune DiabetesChina
-
National Institute of Diabetes and Digestive and...University of Pennsylvania; George Washington UniversityUnknownChronic Kidney DiseasesUnited States